NCT05238701View on ClinicalTrials.gov

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

November 4, 2023

Study Completion Date

November 4, 2023

Conditions
Huntington DiseaseTardive Dyskinesia
Interventions
DRUG

LPM3770164 sustained release tablet

LPM3770164 sustained release tablet will be administrated orally single-dose on day 1

DRUG

LPM3770164 sustained release tablet simulant

LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1

Trial Locations (1)

Unknown

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY